Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Inv. presentation
Zentalis Pharmaceuticals, Inc. (ZNTL) Create: Alert

All | News | Filings
Date FiledTypeDescription
10/10/2023 SC 13G EVENTIDE ASSET MANAGEMENT, LLC reports a 11.1% stake in Zentalis Pharmaceuticals, Inc.
10/06/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
10/04/2023 144 Form 144 - Report of proposed sale of securities:
10/04/2023 144 Form 144 - Report of proposed sale of securities:
10/04/2023 144 Form 144 - Report of proposed sale of securities:
08/09/2023 8-K Investor presentation
Docs: "Corporate Presentation August 2023 Nasdaq: ZNTL Exhibit 99.1 2 Forward Looking Statement and Disclaimer Zentalis Pharmaceuticals, Inc."
08/09/2023 10-Q Quarterly Report for the period ended June 30, 2023
08/09/2023 8-K Quarterly results
Docs: "Zentalis Pharmaceuticals Reports Second Quarter 2023 Financial Results and Operational Updates Azenosertib monotherapy achieved an ORR of 36.8% in heavily pretreated platinum-resistant ovarian cancer and USC patients who received intermittent dosing"
06/16/2023 8-K Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders...
Docs: "CERTIFICATE OF AMENDMENT TO"
05/31/2023 144 Form 144 - Report of proposed sale of securities:
05/31/2023 144 Form 144 - Report of proposed sale of securities:
05/26/2023 8-K Regulation FD Disclosure, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Zentalis Announces Presentation of Positive Phase 1b Data Demonstrating Durable Responses and Favorable Safety Profile of Azenosertib in Combination with Chemotherapy at the 2023 ASCO Annual Meeting Strong anti-tumor activity shown in a platinum-resistant ovarian cancer population, with a confirmed ORR of 50.0% and mPFS of 7.4 months in combination with paclitaxel, and a confirmed ORR of 35.7% and mPFS of 10.4 months in combination with carboplatin"
05/10/2023 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
05/10/2023 10-Q Quarterly Report for the period ended March 31, 2023
05/10/2023 8-K Quarterly results
Docs: "Zentalis Pharmaceuticals Reports First Quarter 2023 Financial Results and Operational Updates On track to disclose monotherapy dose and updates on currently accruing trials for azenosertib, a potentially first-in-class and best-in-class WEE1 inhibitor, in 1H 2023"
04/28/2023 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
04/28/2023 ARS Form ARS - Annual Report to Security Holders:
04/28/2023 DEF 14A Form DEF 14A - Other definitive proxy statements:
04/26/2023 8-K Quarterly results
04/18/2023 PRE 14A Form PRE 14A - Other preliminary proxy statements:
04/17/2023 8-K Quarterly results
03/10/2023 8-K Regulation FD Disclosure  Interactive Data
03/09/2023 8-K Entry into a Material Definitive Agreement  Interactive Data
03/01/2023 10-K Annual Report for the period ended December 31, 2022
02/14/2023 SC 13G/A PRICE T ROWE ASSOCIATES INC reports a 3.8% stake in ZENTALIS PHARMACEUTICALS INC
02/14/2023 SC 13G/A Avidity Partners Management LP reports a 9% stake in Zentalis Pharmaceuticals, Inc.
02/14/2023 SC 13G TYBOURNE CAPITAL MANAGEMENT LTD reports a 3.9% stake in Zentalis Pharmaceuticals, LLC
02/13/2023 SC 13G Form SC 13G - Statement of acquisition of beneficial ownership by individuals:
02/13/2023 8-K Quarterly results
02/09/2023 SC 13G/A Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
02/09/2023 SC 13G/A Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
02/07/2023 SC 13G STATE STREET CORP reports a 5.4% stake in INITIAL FILING ZENTALIS PHARMACEUTICALS INC
02/06/2023 SC 13G Form SC 13G - Statement of acquisition of beneficial ownership by individuals:
02/01/2023 SC 13G/A Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy